Avacta Group Plc announced the appointment of seasoned scientific leader Michelle Morrow, PhD as Chief Scientific Officer with effect from November 4, 2024. Dr. Morrow brings nearly 20 years? experience in oncology therapeutics and antibody research at both biotech and pharmaceutical companies.
She will fill a key role in the management team at Avacta as the Company evolves into a therapeutics-focused biotech. She most recently served at invoX Pharma as Senior Vice President (SVP), Head of invoX Therapeutics Innovation, leading a discovery and preclinical research team that was established following the Company?s acquisition of F-star Therapeutics, where she held the position of SVP, Head of Research. During her time at F-star, Dr. Morrow made significant contributions to progressing bispecific candidates from discovery and into clinical trials and led F-star?s biology and translational research functions.
Prior to that, she established an immuno-oncology preclinical modelling group supporting projects across the Medimmune and AstraZeneca portfolio and held Discovery Project Leader roles for Imfinzi, an approved anti-PD-L1 antibody, and volrustomig, an anti- PD-1/CTLA-4 bispecific antibody. Dr. Morrow earned her PhD in Immunology from the University of Cambridge, UK and conducted post-doctoral research into childhood leukaemia at the Institute of Child Health, London.
